Harmony Biosciences Holdings Stock Alpha and Beta Analysis
| HRMY Stock | USD 34.71 0.64 1.88% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Harmony Biosciences Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Harmony Biosciences over a specified time horizon. Remember, high Harmony Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Harmony Biosciences' market risk premium analysis include:
Beta 1.05 | Alpha (0.15) | Risk 3.89 | Sharpe Ratio 0.0093 | Expected Return 0.0361 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Harmony |
Harmony Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Harmony Biosciences market risk premium is the additional return an investor will receive from holding Harmony Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Harmony Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Harmony Biosciences' performance over market.| α | -0.15 | β | 1.05 |
Harmony Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Harmony Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Harmony Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Harmony Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Harmony Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Harmony Biosciences shares will generate the highest return on investment. By understating and applying Harmony Biosciences stock market price indicators, traders can identify Harmony Biosciences position entry and exit signals to maximize returns.
Harmony Biosciences Return and Market Media
The median price of Harmony Biosciences for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 35.5 with a coefficient of variation of 5.91. The daily time series for the period is distributed with a sample standard deviation of 2.11, arithmetic mean of 35.75, and mean deviation of 1.67. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 8013 shares by Kapadia Sandip of Harmony Biosciences at 33.58 subject to Rule 16b-3 | 09/13/2024 |
2 | Did Harmony Biosciences Holdings, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate - HRMY | 10/07/2024 |
3 | Harmony Biosciences Q3 2024 Earnings EPS of 0.79 Beats Estimates, Revenue Hits 186 Million | 10/29/2024 |
4 | Harmony Biosciences prices secondary offering at 31 per share | 10/31/2024 |
5 | Are Investors Undervaluing Harmony Biosciences Right Now | 11/01/2024 |
6 | Levi Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. Regarding Potential Securities Fraud Allegations | 11/04/2024 |
7 | Harmony Biosciences Holdings, Inc. is AlphaCentric Advisors LLCs 2nd Largest Position | 11/05/2024 |
8 | ATTENTION Harmony Biosciences Holdings, Inc. Investors You May Have Been Affected by Fraud- Contact Levi Korsinsky to Discuss Your Rights | 11/06/2024 |
9 | Harmony Biosciences Holdings, Inc. Investigation Ongoing Contact Levi Korsinsky About Potential Securities Fraud Allegations - HRMY | 11/08/2024 |
10 | An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi Korsinsky to Discuss your HRMY Losses. | 11/13/2024 |
11 | Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi Korsinsky Regarding Potential Securities Law Vio... | 11/20/2024 |
About Harmony Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Harmony or other stocks. Alpha measures the amount that position in Harmony Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 55.46 | 22.05 | 6.84 | 12.74 | Days Of Inventory On Hand | 29.14 | 18.79 | 16.15 | 15.34 |
Harmony Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Harmony Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Harmony Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Harmony Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Harmony Biosciences. Please utilize our Beneish M Score to check the likelihood of Harmony Biosciences' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Harmony Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.